An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.
about
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromesGastrointestinal neuroendocrine tumors: pancreatic endocrine tumorsPharmacotherapy of Zollinger-Ellison syndrome.Gastric acid hypersecretory states: recent insights and advances.Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.
P2860
An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
An open-label study of rabepra ...... c gastric acid hypersecretion.
@en
An open-label study of rabepra ...... c gastric acid hypersecretion.
@nl
type
label
An open-label study of rabepra ...... c gastric acid hypersecretion.
@en
An open-label study of rabepra ...... c gastric acid hypersecretion.
@nl
prefLabel
An open-label study of rabepra ...... c gastric acid hypersecretion.
@en
An open-label study of rabepra ...... c gastric acid hypersecretion.
@nl
P2093
P2860
P1476
An open-label study of rabepra ...... c gastric acid hypersecretion.
@en
P2093
A Morocutti
M Merrouche
T Bjaaland
T Humphries
P2860
P304
P356
10.1111/J.1365-2036.2006.03137.X
P407
P577
2006-11-01T00:00:00Z